Research Abstracts

Inhibition studies to direct oral immunotherapy in walnut-hazelnut co-allergic patients (nut CRACKER study).

Koren, Y., M.Y. Appel, M. Elkan, L. Nachshon, L. Mattsson, J. Lidholm, M.B. Levy, A. Elizur, M.R. Goldberg, 2026. Inhibition studies to direct oral immunotherapy in walnut-hazelnut co-allergic patients (nut CRACKER study). Pediatr Allergy Immunol. 37:e70500. doi:10.1111/pai.70500

Background: Walnut OIT has been observed to induce cross-desensitization to hazelnut, but predictors of this response remain unclear. We sought to identify molecular predictors of hazelnut cross-desensitization following walnut OIT, to help guide treatment decisions in these co-allergic patients. Methods: Patients with confirmed IgE-mediated walnut and hazelnut allergy underwent walnut OIT. Patients achieving full walnut desensitization to 4 g of walnut protein were re-challenged to 4-grams hazelnut protein after 6 months. Baseline sera were obtained and competitive ELISA inhibition assays performed to evaluate serum IgE cross-recognition of total walnut, total hazelnut and hazelnut component-specific IgE. Results were compared between patients fully (4-grams protein) or clinically (≥30-fold ED increase or mild reaction at full dose) cross-desensitized to hazelnut and those who remained hazelnut allergic following walnut OIT. Results: Overall, 12/22 (54.5%) patients were fully cross-desensitized, and 14/22 (63.6%) patients were clinically cross-desensitized to hazelnut following walnut OIT. Among the latter, walnut inhibited total hazelnut-specific IgE binding by a median of 95%, compared to 55% in those who remained hazelnut allergic (p < .01). Similarly, walnut extract competed for IgE binding to hazelnut components Cor a 9 (p = .003) and Cor a 16 (p = .023) in the cross-desensitized group following walnut OIT, but not in the persistent hazelnut allergic group. A ≥70% inhibition threshold accurately predicted cross-desensitization in 93% of cases (p < .001). Conclusion: Walnut OIT can induce clinical cross-desensitization to hazelnut in >60% of co-allergic individuals. Competitive ELISA inhibition is a promising predictive tool, with potential to guide targeted and efficient OIT strategies in walnut-hazelnut co-allergic patients.